Hepatitis B in HIV-infected patients

Area of Science:

• Hepatology
• Virology
• Infectious Diseases

Background:

• Chronic hepatitis B virus (HBV) infection frequently co-occurs with HIV.
• HIV accelerates HBV-related liver disease, increasing risks of hepatic failure and cancer.
• Standard HBV vaccination yields lower protection rates in HIV-positive individuals.

Purpose of the Study:

• To review the management of chronic HBV in HIV-positive individuals.
• To highlight the efficacy of anti-HBV agents and challenges with specific antivirals.

Main Methods:

• Review of current literature on HBV/HIV co-infection.
• Analysis of treatment outcomes with anti-HBV therapies.
• Discussion of drug resistance and vaccine escape mechanisms.

Main Results:

• Tenofovir-based regimens are effective in managing chronic HBV in HIV patients.
• Lamivudine monotherapy is associated with high rates of drug resistance and cross-resistance.
• Drug resistance can compromise long-term treatment benefits and lead to HBV vaccine escape mutants.

Conclusions:

• Effective management of chronic HBV in HIV-positive individuals is crucial.
• Tenofovir is a preferred agent for anti-HBV therapy in this population.
• Careful consideration of antiviral choice is needed to prevent resistance and maintain vaccine efficacy.